ARISTOCORT
LOE ApproachingNDAORALTABLETPriority Review
Approved
Dec 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 5h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ARISTOCORT is an oral tablet small-molecule NDA approved in 1957 by Astellas with unknown mechanism of action and indication profile. The specific therapeutic mechanism and patient population cannot be determined from available data.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30), suggesting the brand team is likely in transition or defensive positioning mode.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job postings indicate this product currently has minimal active hiring or career mobility opportunities. Working on ARISTOCORT represents a defensive, maintenance-focused role rather than growth opportunity.
Brand ManagerMarket Access Specialist
Worked on ARISTOCORT at Astellas? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.